Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Alzheimer’s and Neurodegenerative Disease Treatment

Technology #20110150

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Early Onset Alzheimer'sGlycation PreventionNeurodegenerative DiseaseAcetaminophen OverdoseGSHAlzheimer’s Disease
Categories
Researchers
Robert Vince, PhD
Director, Center for Drug Design
External Link (drugdesign.umn.edu)
Swati More, PhD
Assistant Professor, Center for Drug Design
External Link (drugdesign.umn.edu)
Managed By
Kevin Nickels
Technology Licensing Officer 612-625-7289
Patent Protection

US Patent Pending 20140154192

GSH Analogs

A pharmaceutical compound consisting of stable glutathione (GSH) analogs has been developed to treat Alzheimer's disease (AD) and other neurodegenerative disorders. The GSH analogs fulfill key roles of endogenous GSH and resist enzyme breakdown while acting as a substrate for the detoxifying enzyme glyoxalase-I.

Decreases Glycation and Amyloid-beta Plaques

The GSH analogs treat AD through two mechanisms. Amyloid-beta (Aβ) plaques, a hallmark of AD and other neurodegenerative diseases, are caused by Aβ protein aggregation. Aβ aggregation is induced through glycation. Glyoxalase-I curbs glycation; but this process is dependent on GSH, which is severely depleted in an AD-affected brain. The new GSH analogs treat AD progression by restoring glyoxalase-I activity in the brain, which decreases glycation, and hampers glycation-induced Aβ aggregation, and in turn, plaque formation.

Neutralizes Oxidative Stress

The GSH analogs are able to pass through the blood-brain barrier to neutralize oxidative stress in the brain. Oxidative stress is a root cause of neurodegenerative disorders, as well as other diseases.

Replicates Endogenous GSH Activity

The new GSH analogs are the first compounds to replicate endogenous GSH activity while resisting breakdown. Other compounds which have tried to mimic the role of GSH failed because they were not resistant to breakdown. This treatment could be used in conjunction with other AD treatments, or used independently. This AD treatment can be used earlier than any other existing treatments.

Hepatoprotective Qualities

Separately, the GSH analogs were found to have hepatoprotective qualities. The analogs react directly with N-acetyl-p-benzoquinoneimine (NAPQI), a toxic by-product produced during acetaminophen metabolism. Using the GSH analogs in combination with acetaminophen could improve overall safety. The analogs could also act as a rescue treatment for acute acetaminophen overdose.

BENEFITS AND FEATURES OF GSH ANALOGS COMPOUND:

  • Helps prevent harmful glycation and Aβ plaque formation
  • Treats AD earlier than other treatments
  • Can be used in combination with other treatments or independently
  • Antioxidant properties treats root cause of neurodegenerative disease
  • Has hepatoprotective qualities and could be used with acetaminophen

Phase of Development In vitro and in vivo data available